Byam Rebecca

Chief Financial Officer | Officer

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001866256

Purchase history

Companies traded: 1
Purchases · 12M: 1
Purchases · 24M: 2
Average purchase: $120.0K
Median purchase: $120.0K
Gross purchase value: $240.1K

Companies: HCW Biologics Inc.

2 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

Published	Company	Ticker	Role	Reported value	SEC source
2026-05-27	HCW Biologics Inc.	HCWB	Chief Financial Officer \| Officer	$20.1K	Open filing
2025-05-09	HCW Biologics Inc.	HCWB	Chief Financial Officer \| Officer	$220.0K	Open filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	2Small Sample	100.0% (2/2)	50.0% (1/2)	+12.8%	+12.8%	-13.9%
20D	2Small Sample	100.0% (2/2)	0.0% (0/2)	-28.2%	-28.2%	-40.4%
60D	2Small Sample	100.0% (2/2)	0.0% (0/2)	-61.4%	-61.4%	-83.6%
120D	1Small Sample	100.0% (1/1)	0.0% (0/1)	-57.9%	-57.9%	-57.9%

Research patterns

First purchase in 12M: 1/1
Large purchase ≥ $100k: 1/2
Cluster buying · 15D: 2/2
Buying the dip: 2/2

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.